Vilin Bio Med Limited is a pharmaceutical manufacturing company based in Roorkee, Uttarakhand. The company has established a strong presence in the domestic market by producing high-quality pharmaceutical products. One of its key strengths lies in its research and development foundation, which allows the company to stay competitive and contribute to the advancement of healthcare.
The manufacturing facility owned by Vilin Bio Med Limited is state-of-the-art, ensuring efficient production processes and adherence to strict quality standards. The company's commitment to quality is evident in its strategy to sell products in bulk to pharmaceutical manufacturers, marketers, and traders, who in turn provide the channel for sales to customers. Villin Bio Med’s products are primarily used by other pharmaceutical companies and traders, who ultimately market them to distributors and retail customers. The company doesn’t sell its products under any brand name. The opening date for Vilin Bio Med Limited IPO is Friday, 16 June 2023, and the closing date is Wednesday, 21 June 2023.
Vilin Bio Med Limited IPO Details
Vilin Bio Med Limited IPO is a 100% fresh issue of 4,000,000 equity shares aggregating up to ₹12 crore. The offer has its price band set to ₹30 per share and the lot size is 4000. The IPO will list on the NSE.
Vilin Bio Med Limited IPO Objective
The objectives of Vilin Bio Med Limited's IPO are listed below:
- Augmenting additional working capital requirements.
- General corporate purposes.
- Issue-related expenses.
Should you invest in Vilin Bio Med Limited?
Here are a few important factors to consider before investing in the IPO:
- Vilin Bio Med Limited is a well-established pharmaceutical manufacturing company. The company is well-positioned to benefit from the growth of the Indian pharmaceutical market.
- The company’s revenue from operations for FY-2022 was ₹1,121.49 lakhs as compared to ₹1,171.52 lakhs during FY 2021 showing a decrease of 4.27%.
- The company has experienced negative cash flows in the past.
Competitive Peers
JFL Life Sciences Limited, Vaishali Pharma Limited, and Anuh Pharma Limited are the listed peer companies operating in the same business line.
Highlights of Vilin Bio Med Ltd
- Vilin Bio Med Limited manufactures a wide range of pharmaceutical formulations, including oral liquids, dry syrups, sachets, external preparations, beta and non-beta lactam tablets, capsules, and nutritional food supplements. The company also provides technology-based products and pre-formulation intermediates, such as oral thin films for pharmaceutical and nutraceutical products.
- Vilin Bio Med Limited prioritises quality manufacturing and aims to deliver products that meet or exceed customer expectations. The presence of an in-house testing laboratory within the manufacturing unit ensures that the products undergo rigorous quality checks.
- The company is a customer satisfaction-oriented company and strives to maintain good relationships with its customers. It continuously strives to increase its sales in the existing states and customers.
Company Financials
| Particulars | For nine months period ended December 31, 2022 (₹ lakhs) | Fiscal 2022 (₹ lakhs) |
|---|---|---|
| Revenue from Operations | 901.29 | 1,121.49 |
| Total Income | 903.43 | 1,121.91 |
| Profit After Tax (PAT) | 128.08 | 3.35 |
| PAT Margin | 14.18% | 0.30% |
| EBITDA | 235.52 | 77.01 |
| EBITDA Margin | 26.07% | 6.86% |
| EPS | 1.55 | 0.04 |
| ROE | 14.76% | 0.45% |
Know before investing
Strengths
2The company has established a strong presence in the domestic market by supplying its products in bulk to pharmaceutical manufacturers, marketers, and traders who serve as channels for distribution to customers.
Vilin Bio Med Limited takes pride in its workforce, which includes experienced senior executives who have been associated with the company for a considerable time. The management team and key personnel possess the necessary qualifications and industry expertise to drive operational growth and ensure the company's success.
Risks
2There are outstanding criminal legal proceedings involving the company which may adversely affect the company’s business, financial condition and results of operations.
The company is reliant on the demand from the pharmaceutical industry for a significant portion of its revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage sales can have an adverse impact on Vilin Bio Med company’s business and results of operations.
